Page last updated: 2024-10-30

ketotifen and Multiple Myeloma

ketotifen has been researched along with Multiple Myeloma in 1 studies

Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.
ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.

Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dennis, M1
Maoz, A1
Hughes, D1
Sanchorawala, V1
Sloan, JM1
Sarosiek, S1

Other Studies

1 other study available for ketotifen and Multiple Myeloma

ArticleYear
Bortezomib ocular toxicities: Outcomes with ketotifen.
    American journal of hematology, 2019, Volume: 94, Issue:3

    Topics: Adult; Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chalazion; Con

2019